Phase IIA trial testing erlotinib as an intervention against intraductal pancreatic mucinous neoplasms.

Trial Profile

Phase IIA trial testing erlotinib as an intervention against intraductal pancreatic mucinous neoplasms.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 24 May 2013

At a glance

  • Drugs Erlotinib (Primary)
  • Indications Pancreatic cancer
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 01 Dec 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 08 Mar 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 20 Apr 2010 Additional lead trial investigator (Schnoll-Sussman F) identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top